{"filings":[{"id":695919,"accession_number":"0001104659-26-066956","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-05-27T20:15:26+00:00","items":["1.02"],"status":"ready","headline":"Passage Bio terminates Gemma collaboration and exits Philadelphia office lease with $2.3M fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, effective May 21, 2026.","Termination also eliminates options for four new CNS indications under the July 2024 agreement.","Paid $2.3M to exit 37,000 sq ft office lease (originally expiring Dec 2031); company is remote-only.","Subleases previously covered substantially all of that office space."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649237,"accession_number":"0001104659-26-065991","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-05-26T11:15:24+00:00","items":["5.07"],"status":"ready","headline":"Passage Bio stockholders elect two Class III directors, ratify KPMG, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Athena Countouriotis and Sandip Kapadia elected as Class III directors for three-year terms.","KPMG LLP ratified as independent auditor for FY2026 (2,083,031 for, 41,539 against).","Non-binding advisory vote on executive compensation approved (1,452,505 for, 36,352 against).","Stockholders favored holding say-on-pay vote every year; board adopts annual frequency policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95451,"accession_number":"0001104659-26-049755","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Passage Bio cuts ~75% of workforce, expects $3.3M in severance costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of approximately 75%; substantial completion expected in Q2 and Q3 2026.","Aggregate severance and exit costs estimated at $3.3 million, primarily recorded in Q2 2026.","Restructuring part of previously announced strategic alternatives review to maximize shareholder value.","Severance benefits contingent on execution of release of claims by impacted employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95450,"accession_number":"0001104659-26-045219","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PBFT02 cuts brain atrophy 64% vs natural history; FDA demands randomized trial; strategic review begun","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PBFT02 patients with global CDR 1 at baseline showed 64% less whole brain atrophy (3.1% vs 8.7%) at 12 months vs ALLFTD natural history.","FDA Type C meeting indicated a randomized controlled registrational trial is required for PBFT02 in FTD-GRN.","Company initiated a review of strategic alternatives including merger, sale, or licensing; engaged Wedbush PacGrow as advisor.","No new treatment-related SAEs; prior asymptomatic SAEs (venous sinus thrombosis, hepatotoxicity) remain unchanged.","Plasma NfL stabilized at 12 months (average -1.0 pg/mL) vs +13.5 pg/mL in untreated natural history patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108537,"accession_number":"0001104659-26-025550","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Passage Bio terminates Hopewell lease; pays $4.8M fee, cash runway to Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated 62,000 sq ft lab lease (15-year term from March 2021) via Termination Agreement dated March 4, 2026.","Company paid ~$4.8M termination fee plus accrued rent through February 14, 2026.","All operations at Hopewell facility ceased after January 2025 restructuring.","Company expects existing cash to fund operations through Q1 2027, but actual burn may differ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108536,"accession_number":"0001104659-26-022539","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio reports 2025 net loss of $45.5M; cash runway through Q1 2027; advances FTD clinical program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $46.3M at Dec 31, 2025; funding expected through Q1 2027.","Net loss of $45.5M ($14.35/diluted share) for 2025, improved from $64.8M ($21.04/sh) in 2024.","R&D expenses $23.3M in 2025, down from $40.2M in 2024; G&A $19.9M vs $25.0M.","Enrolled first 3 FTD-GRN patients in Cohort 3; dosed first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4.","Expects interim safety/biomarker data and regulatory feedback on FTD-GRN registrational trial in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108535,"accession_number":"0001104659-26-002696","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio reports preliminary cash ~$46M as of Dec 31, 2025; runway into Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of approximately $46 million as of December 31, 2025.","Company expects the cash position to fund operating expenses and capital expenditures into the first quarter of 2027.","Amount is preliminary, subject to completion of year-end financial review, adjustments, and audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124984,"accession_number":"0001104659-25-109158","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio Q3 net loss $7.7M; cash runway into 1Q 2027; FTD trial enrollment ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $52.8M as of Sep 30, 2025; expected to fund operations into 1Q 2027.","Net loss narrowed to $7.7M ($2.44 per share) vs $19.3M ($6.15) in Q3 2024; R&D and G&A expenses declined.","Enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) in upliFT-D study; interim data expected in 1H 2026.","Aligned with FDA on analytical comparability plan for suspension-based PBFT02 manufacturing process.","On track for FDA feedback on FTD-GRN registrational trial design in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141677,"accession_number":"0001104659-25-091288","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Saqib Islam resigns from Passage Bio board; Athena Countouriotis appointed to audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Saqib Islam resigned from Board and Audit Committee effective Sept 16, 2025; no disagreement with company.","Board appointed Athena Countouriotis, M.D., to Audit Committee to fill vacancy.","Board size reduced from eight to seven members effective same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141676,"accession_number":"0001558370-25-011143","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio Q2 net loss narrows to $9.4M; cash runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities: $57.6M as of June 30, 2025 vs $91.8M a year ago; runway into Q1 2027.","Net loss of $9.4M ($2.96 per share) vs $16.0M ($5.09 per share) in Q2 2024 (adjusted for 1-for-20 reverse split).","Completed dosing of FTD-GRN Cohort 2 in upliFT-D study; all four patients treated with PBFT02.","Updated interim data: PBFT02 showed robust, durable CSF PGRN elevation and improved plasma NfL biomarker vs natural history.","Amended upliFT-D protocol submitted to trial sites and health authorities; plan to enroll Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72)."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141675,"accession_number":"0001104659-25-071779","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Passage Bio regains Nasdaq minimum bid price compliance; listing matter closed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on July 28, 2025 confirming compliance with Listing Rule 5450(a)(1).","Closing bid price was at least $1.00 per share for 10 consecutive business days as of July 28.","Had been non-compliant since August 1, 2024 due to bid price below $1.00 for 30 consecutive days.","Listing matter now closed; company continues on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141674,"accession_number":"0001104659-25-067561","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Passage Bio announces 1-for-20 reverse stock split effective July 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20; effective 12:01 a.m. ET on July 14, 2025.","Pre-split shares ~62.4M; post-split ~3.12M shares outstanding.","Action intended to regain Nasdaq minimum $1.00 bid price compliance.","No fractional shares; holders of fractional shares receive rounded-up whole share.","No change to authorized shares (125M), par value ($0.0001), or voting rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159573,"accession_number":"0001104659-25-061371","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PBFT02 Phase 1/2 data: durable PGRN boost; new pulmonary embolism SAE, protocol to add anticoagulation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to mean 25.9 ng/mL at 12 months (n=4); Dose 2 patient rose to 7.6 ng/mL at 1 month.","Plasma NfL increased only 4% in treated patients vs expected 28-29% per year in natural history, suggesting slowed disease progression.","Three of eight patients had four SAEs, including new pulmonary embolism in Dose 2 patient (Patient 8) possibly related; responded to anticoagulants.","Company plans to amend upliFT-D protocol to add prophylactic low-dose anticoagulation and restrict enrollment to earlier-stage patients; Patient 9 may proceed with extra monitoring.","Milestones: submit amendment July 2025; report Dose 2 interim data 1H 2026; seek regulatory feedback on registrational trial design 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159572,"accession_number":"0001104659-25-054907","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Passage Bio stockholders elect two directors, ratify KPMG, authorize reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maxine Gowen, Ph.D. and Dolan Sondhi, Ph.D. elected as Class II directors for three-year terms.","Ratification of KPMG LLP as independent auditor for FY 2025 with 49.46M shares for, 70.7K against.","Approval granted for Board to implement reverse stock split at ratio 1:5 to 1:50, by Dec 31, 2025.","No broker non-votes on proposals 2 and 3; 13.59M broker non-votes on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159571,"accession_number":"0001558370-25-007487","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio Q1 2025 net loss $15.4M; cash runway into Q1 2027; first FTD-GRN patient dosed at Dose 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.4M ($0.25 per share) vs $16.7M ($0.30 per share) in Q1 2024.","Cash, cash equivalents and marketable securities $63.4M as of Mar 31, 2025; funding expected into Q1 2027.","First FTD-GRN patient dosed with Dose 2 PBFT02; second patient enrolled; additional patients being evaluated.","Enrollment opened for FTD-C9orf72 patients in the upliFT-D study, targeting up to five symptomatic patients.","R&D expenses decreased to $7.7M from $11.5M; G&A expenses were $6.1M vs $6.5M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177946,"accession_number":"0001558370-25-002093","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio reports FY2024 net loss $64.8M, cash $76.8M; PBFT02 shows durable PGRN elevation in FTD-GRN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $76.8M as of Dec 31, 2024, down from $114.3M; runway extended into 1Q 2027.","Net loss of $12.7M ($0.20 per share) for Q4 2024 vs $16.8M ($0.30) a year ago; full year net loss $64.8M ($1.07) vs $102.1M.","Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to 13-27 ng/mL at 6 months (n=4) and 22-34 ng/mL at 12 months (n=2).","Plasma NfL levels 13% lower vs baseline at 12 months vs expected 29% annual increase from natural history data.","First FTD-GRN patient enrolled with Dose 2 (50% lower); plan to report 12-month data and interim Dose 2 data in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177945,"accession_number":"0001104659-25-008100","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Passage Bio transfers listing to Nasdaq Capital Market; granted 180-day extension to meet $1.00 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Aug 1, 2024 for bid price below $1.00 for 30 consecutive days.","Nasdaq approved transfer to Capital Market effective Jan 30, 2025; stock continues trading under PASG.","Granted additional 180-day compliance period until July 28, 2025 to regain $1.00 minimum bid price.","Company will monitor and consider options including reverse stock split if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177944,"accession_number":"0001104659-25-002278","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","2.05","2.06","7.01","8.01","9.01"],"status":"ready","headline":"Passage Bio cuts workforce 55%, extends cash runway into Q1 2027; updates PBFT02 data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash $76.8M as of Dec 31, 2024; expected runway into Q1 2027 after restructuring.","Workforce reduced ~55%; lab operations in Hopewell, NJ ceased; annual cost savings $9-11M; severance $2M.","Expects $1-3M impairment on lab equipment in Q1 2025; non-cash, no impact on cash runway.","PBFT02 (FTD-GRN) interim data: CSF PGRN increased from <3 to 13-27 ng/mL at 6 months (n=4), durable to 18 months.","Plasma NfL decreased 13% vs baseline at 12 months (n=2); vs 29% annual increase in untreated per literature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194654,"accession_number":"0001558370-24-015429","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio Q3 net loss $19.3M; 4 patients enrolled in FTD-GRN Cohort 2; cash to Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.3M ($0.31/share) vs $27.1M loss a year ago; R&D expenses fell to $8.7M from $15.1M.","Cash and securities $84.8M at Sept 30, 2024; expected runway to end Q2 2026.","Enrolled 4 patients in Cohort 2 of upliFT-D trial; 12-month Cohort 1 and interim Cohort 2 data due 1H25.","Interim Cohort 1 data: PBFT02 raised CSF progranulin for up to 12 months; no serious adverse events with enhanced immunosuppression.","Appointed Tom Kassberg (Ultragenyx CBO) to board of directors and Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194653,"accession_number":"0001558370-24-013563","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PBFT02 delivers superior CSF progranulin with AAV1 vector; interim safety and biomarker data promising","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Capsid comparison in NHPs: AAV1 vector achieved superior human PGRN levels in CSF versus AAV5 and AAVhu68 after ICM administration.","In Grn knockout mice, PBFT02 improved lysosomal histopathology and reduced neuroinflammation across brain regions.","Interim clinical data from upliFT-D trial: Dose 1 well-tolerated; durable CSF progranulin increases sustained up to 12 months.","NHP biodistribution showed ICM administration of PBFT02 achieved high gene distribution to cortical and sub-cortical brain regions and spinal cord."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210957,"accession_number":"0001558370-24-012793","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PBFT02 shows robust CSF progranulin increase; well-tolerated with enhanced immunosuppression","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CSF PGRN up to 6-fold at month 1 (10.7-17.3 ng/mL) and up to 10-fold at month 6 (21.7-27.3 ng/mL), exceeding healthy controls (3.3-8.2 ng/mL).","No serious adverse events in patients 2-5 with enhanced immunosuppression; first patient had SAEs with lower steroid regimen.","CSF PGRN remained elevated at 12 months (34.2 ng/mL), with rate of increase slowing from 58% to 26% between months 1-6 and 6-12.","Cohort 2 currently enrolling; Cohort 4 anticipated to open in first half of 2025 for FTD-C9orf72.","Plasma PGRN expression remained below healthy reference levels across all five patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210956,"accession_number":"0001104659-24-098371","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Passage Bio appoints Thomas Kassberg as Class I director and Audit Committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective September 10, 2024; Kassberg also joins Audit Committee.","Kassberg currently Chief Business Officer and EVP at Ultragenyx Pharmaceutical.","Received non-incentive stock options with $90,000 grant date fair value, vesting over three years.","Cash compensation per non-executive director policy plus indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210955,"accession_number":"0001558370-24-012654","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["2.06"],"status":"ready","headline":"Passage Bio expects $3.5M-$5.5M impairment charge on sublease of lab space","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subleased 3,200 sq ft (5% of 62,000 sq ft lab) in Hopewell, NJ; term Sept 2024 to Sept 2029, option to extend to 2032.","Expects pre-tax impairment of $3.5M-$5.5M in Q3 2024 for ROU assets, leasehold improvements, and lab equipment.","Impairment is non-cash; cash runway to fund operations through Q2 2026 unchanged.","Annual sublease rent ~$0.1M (escalates 2.5%/yr); expected to reduce GAAP net loss by $0.1-$0.2M annually.","Company pursuing additional subleases to further offset lease obligations from prior corporate developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210954,"accession_number":"0001558370-24-011459","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio reports Q2 net loss $16M; advances upliFT-D trial, out-licenses programs to GEMMABio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial; FDA agreed to expand trial to FTD-C9orf72 patients.","Out-licensed pediatric LSD programs to GEMMA Biotherapeutics; initial payments $10M, potential milestones up to $114M plus royalties.","Cash $91.8M as of June 30, 2024; cash runway extended to end of Q2 2026.","Net loss $16.0M ($0.26/share) vs $23.9M ($0.44/share) in Q2 2023; R&D and G&A expenses decreased.","Plan to present updated safety and biomarker data from Cohort 1 at ISFTD2024 in September."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210953,"accession_number":"0001104659-24-085360","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Passage Bio receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Aug 1, 2024; closing bid price below $1.00 for 30 consecutive days.","180-day compliance period until Jan 28, 2025 to regain minimum $1.00 bid for 10 days.","If not cured, may seek transfer to Nasdaq Capital Market with additional 180-day grace period.","No decisions on response yet; cannot assure regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210952,"accession_number":"0001104659-24-084615","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["1.01","2.02","5.02","7.01","9.01"],"status":"ready","headline":"Passage Bio out-licenses three pediatric gene therapy programs to GEMMABio, extends cash runway to Q2 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Out-licensed PBGM01, PBKR03, PBML04 to GEMMABio; initial $10M + up to $124M milestones + royalties.","Cash of ~$91.8M at June 30, 2024; operating runway extended to end of Q2 2026.","CMO Mark Forman resigned effective Aug 2, 2024; no disagreement with company.","Appointed Susan Browne as CSO and Stuart Henderson as CBO effective Aug 1, 2024.","Entered new collaboration with GEMMABio to advance CNS programs including Huntington's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210951,"accession_number":"0001558370-24-009826","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Passage Bio gets FDA green light to add FTD-C9orf72 arm to PBFT02 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive Type C meeting feedback from FDA supports evaluating PBFT02 in FTD-C9orf72 patients.","Passage Bio to amend upliFT-D Phase 1/2 global study protocol to include FTD-C9orf72 population.","Company plans to initiate dosing of FTD-C9orf72 patients in first half of 2025.","FTD-C9orf72 affects an estimated 21,000 individuals in the U.S. and Europe.","PBFT02 already has FDA Fast Track and Orphan Drug designations; also Orphan from European Commission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229421,"accession_number":"0001104659-24-064243","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Passage Bio reports stockholder votes: Drs. Chou and Porter elected as Class I directors; KPMG ratified as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["William Chou, M.D. elected with 35,909,628 shares for, 786,951 withheld; 10,034,554 broker non-votes.","Derrell Porter, M.D. elected with 27,072,576 shares for, 9,624,003 withheld; 10,034,554 broker non-votes.","KPMG LLP ratified as auditor for fiscal 2024 with 45,565,348 for, 1,104,311 against, 61,474 abstaining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229420,"accession_number":"0001558370-24-008054","cik":1787297,"company_name":"Passage BIO, Inc.","ticker":"PASG","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Passage Bio Q1 net loss $16.7M, cash $104.5M; PBFT02 shows sustained CSF PGRN in 2 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.7M ($0.30/shr) vs $34.3M a year ago; cash $104.5M, runway through Q4 2025.","Dose 1 PBFT02 elevated CSF progranulin (21.7–27.3 ng/mL) at 6 months in 2 FTD-GRN patients.","Completed dosing Cohort 1 (n=5) in upliFT-D trial; 6-month safety/biomarker data due 2H 2024.","Plan to initiate Cohort 2 dosing in 1H 2024; FDA feedback sought for FTD-C9orf72 indication.","Raised $8.7M net under ATM facility in Q1 2024; R&D expenses $11.5M, G&A $6.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18124127.318840582,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}